Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 13/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3372288 | 0.94 | CYP3A4 (0.65) | CYP3A4CTSBELANEROCK2 | |
| SCHEMBL8142617 | 0.94 | CYP3A4 (0.65) | CYP3A4CTSBELANEROCK2 | |
| SCHEMBL8149983 | 0.93 | CYP3A4 (0.64) | CYP3A4CTSBELANEROCK2 | |
| SCHEMBL3408415 | 0.87 | CYP3A4 (0.64) | CYP3A4CTSBELANE | |
| SCHEMBL3373503 | 0.86 | CYP3A4 (0.49) | CYP3A4CTSBROCK2P2RX3KDM4E | |
| SCHEMBL8134019 | 0.86 | CYP3A4 (0.49) | CYP3A4CTSBROCK2P2RX3KDM4E | |
| SCHEMBL15213304 | 0.86 | CYP3A4 (0.55) | CYP3A4CTSBELANE | |
| SCHEMBL16318497 | 0.86 | CYP3A4 (0.55) | CYP3A4CTSBELANE | |
| SCHEMBL16318495 | 0.86 | CYP3A4 (0.55) | CYP3A4CTSBELANE | |
| SCHEMBL8131033 | 0.86 | CYP3A4 (0.56) | CYP3A4CTSBELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809267-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2162432-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090142257-A1 | Inorganic hydrogen compounds and applications thereof | BLACKLIGHT POWER, INC. | 2009-06-04 | — | — | US | disclosed |
| US-20090136853-A1 | Hydride battery | BLACKLIGHT POWER, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090129992-A1 | Reactor for Preparing Hydrogen Compounds | BLACKLIGHT POWER, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090130016-A1 | Doped thermionic cathode and method of making doped thermionic cathode | BLACKLIGHT POWER, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090123360-A1 | Inorganic hydrogen compounds | BLACKLIGHT POWER, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090123356-A1 | Inorganic hydrogen compounds | BLACKLIGHT POWER, INC. | 2009-05-14 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CTSB 630/4885ELANE 1237/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CTSB 630/4885ELANE 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.